Haemonetics price target lowered to $100 from $125 at JMP Securities

JMP Securities lowered the firm’s price target on Haemonetics (HAE) to $100 from $125 and keeps an Outperform rating on the shares. Haemonetics reported an “uncharacteristically choppy” quarter, with Plasma and Hospital revenues coming in a bit below consensus, and the recently added Opsens and Attune technologies also falling a bit short of expectations, while management lowered its fiscal target growth ranges for these two divisions, the analyst tells investors in a research note. JMP still believes the company’s new products offer the most value in the plasma collection industry.